Parag Shah
Geen lopende functies
Vermogen: 1 359 $ op 30-04-2024
Profiel
Parag Suresh Shah worked as a Director of Pharmaceutical Science at Ikaria, Inc. and later as a Vice President of Business Operations at Bellerophon Therapeutics, Inc. He received an undergraduate degree from Carnegie Mellon University and a doctorate degree from The University of Texas at Austin.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 31-10-2023 | 24 705 ( 0.20% ) | 1 359 $ | 30-04-2024 |
Eerdere bekende functies van Parag Shah
| Bedrijven | Functie | Einde |
|---|---|---|
| BELLEROPHON THERAPEUTICS, INC. | Operationeel Directeur | 31-08-2023 |
| IKARIA, INC. | Corporate Officer/Principal | - |
Opleiding van Parag Shah
| Carnegie Mellon University | Undergraduate Degree |
| The University of Texas at Austin | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| BELLEROPHON THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Ikaria, Inc.
 Ikaria, Inc. BiotechnologyHealth Technology Ikaria, Inc. operates as a biotherapeutics company focused on developing and commercializing innovative therapeutics and interventions designed to meet the medical needs of critically ill patients. It offers INOMAX for inhalation, which is used to treat newborns suffering from hypoxic respiratory failure, and is making a major impact on the critical care environment. The company was founded on August 18, 2006 and is headquartered in Clinton, NJ. | Health Technology |
